Yunliang Yang Selected Research

Thalidomide (Thalomid)

1/2018	Administrations of thalidomide into the rostral ventromedial medulla produce antinociceptive effects in a rat model of postoperative pain.
12/2016	Thalidomide Promotes Morphine Efficacy and Prevents Morphine-Induced Tolerance in Rats with Diabetic Neuropathy.
1/2016	Thalidomide represses inflammatory response and reduces radiculopathic pain by inhibiting IRAK-1 and NF-κB/p38/JNK signaling.
1/2016	Administrations of thalidomide into the rostral ventromedial medulla alleviates painful diabetic neuropathy in Zucker diabetic fatty rats.
11/2015	Prolonged Suppression of Neuropathic Pain by Sequential Delivery of Lidocaine and Thalidomide Drugs Using PEGylated Graphene Oxide.
6/2015	Involvement of peripheral TRPV1 channels in the analgesic effects of thalidomide.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Yunliang Yang Research Topics

Disease

4	Hyperalgesia 01/2018 - 11/2015
2	Diabetic Neuropathies (Diabetic Neuropathy) 12/2016 - 01/2016
2	Pain (Aches) 01/2016 - 06/2015
2	Neuralgia (Stump Neuralgia) 01/2016 - 11/2015
1	Postoperative Pain 01/2018
1	Peripheral Nervous System Diseases (PNS Diseases) 01/2017
1	Intervertebral Disc Degeneration 01/2016
1	Inflammation (Inflammations) 01/2016
1	Type 2 Diabetes Mellitus (MODY) 01/2016
1	Multiple Myeloma 06/2015
1	Myelodysplastic Syndromes (Myelodysplastic Syndrome) 06/2015
1	Vomiting 01/2015
1	Nausea 01/2015
1	Stupor 01/2015
1	Hiccup (Hiccups) 01/2015
1	Cleft Lip (Harelip) 01/2015
1	Respiratory Insufficiency (Respiratory Failure) 01/2015
1	Emergence Delirium 01/2015
1	Laryngismus (Laryngospasm) 01/2015
1	Chills 01/2015
1	Renal Insufficiency (Renal Failure) 04/2014
1	Infections 04/2014
1	Hemorrhage 04/2014

Drug/Important Bio-Agent (IBA)

6	Thalidomide (Thalomid)FDA Link 01/2018 - 06/2015
1	Cannabinoid Receptors (Cannabinoid Receptor)IBA 01/2018
1	N- (2- (3,4- Dichlorphenyl)ethyl)- N,N',N'- trimethyl- 1,2- ethandiaminIBA 01/2017
1	N-Methyl-D-Aspartate Receptors (NMDA Receptors)IBA 01/2017
1	Sigma-1 ReceptorIBA 01/2017
1	Analgesics (Analgesic Drugs)IBA 12/2016
1	Opioid Analgesics (Opioids)IBA 12/2016
1	Morphine (MS Contin)FDA LinkGeneric 12/2016
1	Matrix Metalloproteinases (MMPs)IBA 01/2016
1	graphene oxideIBA 11/2015
1	Ether (Diethyl Ether)IBA 11/2015
1	Lidocaine (Xylocaine)FDA LinkGeneric 11/2015
1	Nitric Oxide (Nitrogen Monoxide)FDA Link 11/2015
1	Interleukin-6 (Interleukin 6)IBA 11/2015
1	CytokinesIBA 11/2015
1	Ethylene Glycol (Monoethylene Glycol)IBA 11/2015
1	Acetic Acid (Vinegar)FDA LinkGeneric 06/2015
1	Hypnotics and Sedatives (Sedatives)IBA 06/2015
1	AntiemeticsIBA 06/2015
1	Inhalation AnestheticsIBA 01/2015
1	Sevoflurane (Ultane)FDA LinkGeneric 01/2015

Therapy/Procedure

1	General Anesthesia 01/2015
1	Anesthesia 01/2015
1	Oxygenators 04/2014